Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015
This article was originally published in The Pink Sheet Daily
Executive Summary
Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.